MX2017000836A - Composiciones inmunogenicas basadas en listeria para inducir respuestas antitumorales. - Google Patents
Composiciones inmunogenicas basadas en listeria para inducir respuestas antitumorales.Info
- Publication number
- MX2017000836A MX2017000836A MX2017000836A MX2017000836A MX2017000836A MX 2017000836 A MX2017000836 A MX 2017000836A MX 2017000836 A MX2017000836 A MX 2017000836A MX 2017000836 A MX2017000836 A MX 2017000836A MX 2017000836 A MX2017000836 A MX 2017000836A
- Authority
- MX
- Mexico
- Prior art keywords
- listeria
- tumor
- immunogenic compositions
- tumor responses
- eliciting anti
- Prior art date
Links
- 241000186781 Listeria Species 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000006023 anti-tumor response Effects 0.000 title 1
- 230000002163 immunogen Effects 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 101150082952 ACTA1 gene Proteins 0.000 abstract 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 abstract 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 abstract 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 abstract 1
- 101710164436 Listeriolysin O Proteins 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 241000607479 Yersinia pestis Species 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000002238 attenuated effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se refiere a composiciones que comprenden un inhibidor de un punto de regulación inmunológico o un estimulador de células T o una combinación de estos y una cepa de Listeria recombinante atenuada viva que comprende un polipéptido de fusión que comprende una proteína Listeriolisina O truncada, una proteína ActA truncada, o una secuencia de aminoácidos PEST fusionada a un antígeno asociado al tumor. La invención se refiere, además, a métodos para tratar, proteger contra, e inducir una respuesta inmunitaria contra un tumor o un cáncer, que comprende la etapa de administrar esta.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462026221P | 2014-07-18 | 2014-07-18 | |
| PCT/US2015/040922 WO2016011362A1 (en) | 2014-07-18 | 2015-07-17 | Listeria-based immunogenic compositions for eliciting anti-tumor responses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017000836A true MX2017000836A (es) | 2017-11-17 |
Family
ID=55079089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017000836A MX2017000836A (es) | 2014-07-18 | 2015-07-17 | Composiciones inmunogenicas basadas en listeria para inducir respuestas antitumorales. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20180064765A1 (es) |
| EP (1) | EP3169355A4 (es) |
| JP (1) | JP2017522322A (es) |
| KR (1) | KR20170063505A (es) |
| CN (1) | CN106794235A (es) |
| AU (1) | AU2015289449A1 (es) |
| CA (1) | CA2955432A1 (es) |
| IL (1) | IL249671A0 (es) |
| MA (1) | MA40061A (es) |
| MX (1) | MX2017000836A (es) |
| SG (1) | SG11201700090RA (es) |
| WO (1) | WO2016011362A1 (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9012141B2 (en) | 2000-03-27 | 2015-04-21 | Advaxis, Inc. | Compositions and methods comprising KLK3 of FOLH1 antigen |
| EP2683400A4 (en) | 2011-03-11 | 2014-09-17 | Advaxis | ADJUVANZIA ON LISTERIA BASE |
| SG11201405605VA (en) | 2012-03-12 | 2014-10-30 | Advaxis Inc | SUPPRESSOR CELL FUNCTION INHIBITION FOLLOWING <i>LISTERIA</i> VACCINE TREATMENT |
| WO2015126921A1 (en) | 2014-02-18 | 2015-08-27 | Advaxis, Inc. | Biomarker directed multi-target immunotherapy |
| WO2015164121A1 (en) | 2014-04-24 | 2015-10-29 | Advaxis, Inc. | Recombinant listeria vaccine strains and methods of producing the same |
| MA41644A (fr) | 2015-03-03 | 2018-01-09 | Advaxis Inc | Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation |
| EP3292152A1 (en) | 2015-05-07 | 2018-03-14 | Agenus Inc. | Anti-ox40 antibodies and methods of use thereof |
| US10617758B2 (en) * | 2015-10-09 | 2020-04-14 | Global Biopharma, Inc. | Anti-cancer vaccine combination |
| WO2017096179A1 (en) | 2015-12-02 | 2017-06-08 | Agenus Inc. | Antibodies and methods of use thereof |
| IL259931B2 (en) | 2015-12-16 | 2024-02-01 | Gritstone Bio Inc | Identification of neo-antigens, preparation, and use |
| PL3463436T3 (pl) | 2016-06-02 | 2024-03-04 | Ultimovacs Asa | Szczepionka w połączeniu z inhibitorem immunologicznego punktu kontrolnego do stosowania w leczeniu nowotworów |
| CA3029235A1 (en) * | 2016-07-05 | 2018-01-11 | Advaxis, Inc. | Listeria-based immunogenic compositions comprising wilms tumor protein antigens and methods of use thereof |
| WO2018089628A1 (en) | 2016-11-09 | 2018-05-17 | Agenus Inc. | Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof |
| SG10202105561PA (en) | 2016-11-30 | 2021-07-29 | Advaxis Inc | Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof |
| WO2018134254A1 (en) | 2017-01-17 | 2018-07-26 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| CN111344011B (zh) * | 2017-06-27 | 2024-01-26 | 纽洛可科学有限公司 | 抗fam19a5抗体用于治疗纤维化的用途 |
| MX2020003100A (es) | 2017-09-19 | 2020-08-20 | Advaxis Inc | Composiciones y metodos para la liofilizacion de bacterias o cepas de listeria. |
| CN111465989B (zh) | 2017-10-10 | 2024-06-25 | 磨石生物公司 | 使用热点进行的新抗原鉴别 |
| US20210177955A1 (en) * | 2017-11-08 | 2021-06-17 | Advaxis, Inc. | Immunogenic heteroclitic peptides from cancer-associated proteins and methods of use thereof |
| CN111630602A (zh) | 2017-11-22 | 2020-09-04 | 磨石肿瘤生物技术公司 | 减少新抗原的接合表位呈递 |
| EP3730153A1 (en) | 2019-04-26 | 2020-10-28 | Medizinische Hochschule Hannover | Personalized immunotherapy for treatment of cancer |
| EP3922255A1 (en) * | 2020-06-10 | 2021-12-15 | Prokarium Limited | Cancer therapy |
| AU2022405109A1 (en) * | 2021-12-10 | 2024-06-27 | Georgiamune Inc. | Polypeptide modulators |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120121643A1 (en) * | 2006-03-01 | 2012-05-17 | Dubensky Jr Thomas W | Engineered listeria and methods of use thereof |
| US9017660B2 (en) * | 2009-11-11 | 2015-04-28 | Advaxis, Inc. | Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors |
-
2015
- 2015-07-17 SG SG11201700090RA patent/SG11201700090RA/en unknown
- 2015-07-17 CN CN201580038799.6A patent/CN106794235A/zh active Pending
- 2015-07-17 JP JP2017502693A patent/JP2017522322A/ja active Pending
- 2015-07-17 US US15/326,011 patent/US20180064765A1/en not_active Abandoned
- 2015-07-17 MA MA040061A patent/MA40061A/fr unknown
- 2015-07-17 CA CA2955432A patent/CA2955432A1/en not_active Abandoned
- 2015-07-17 AU AU2015289449A patent/AU2015289449A1/en not_active Abandoned
- 2015-07-17 KR KR1020177000999A patent/KR20170063505A/ko unknown
- 2015-07-17 EP EP15821743.0A patent/EP3169355A4/en not_active Withdrawn
- 2015-07-17 MX MX2017000836A patent/MX2017000836A/es unknown
- 2015-07-17 WO PCT/US2015/040922 patent/WO2016011362A1/en active Application Filing
-
2016
- 2016-12-20 IL IL249671A patent/IL249671A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20170063505A (ko) | 2017-06-08 |
| MA40061A (fr) | 2016-01-21 |
| US20180064765A1 (en) | 2018-03-08 |
| IL249671A0 (en) | 2017-02-28 |
| JP2017522322A (ja) | 2017-08-10 |
| EP3169355A1 (en) | 2017-05-24 |
| EP3169355A4 (en) | 2018-07-25 |
| SG11201700090RA (en) | 2017-02-27 |
| WO2016011362A1 (en) | 2016-01-21 |
| CA2955432A1 (en) | 2016-01-21 |
| CN106794235A (zh) | 2017-05-31 |
| AU2015289449A1 (en) | 2017-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017000836A (es) | Composiciones inmunogenicas basadas en listeria para inducir respuestas antitumorales. | |
| MX2017008187A (es) | Combinacion de vacuna basada en listeria con anticuerpos anti-ox40 o anti-gitr. | |
| MX2016011537A (es) | Metodos y composiciones para aumentar una relacion de celulas t efectoras con respecto a las celulas t reguladoras. | |
| MX2017000838A (es) | Cepa de listeria recombinante que expresa proteinas de fusion con antigenos heterologos y metodos para el uso de estas. | |
| MX2016013985A (es) | Cepas de vacunas de listeria recombinante y metodos para producir las mismas. | |
| CY1122035T1 (el) | Αντισωματα μονης περιοχης που κατευθυνονται εναντι ενδοκυτταρικων αντιγονων | |
| MX2017004897A (es) | Cepas vacunales recombinantes de listeria y metodos para usar las mismas en la inmunoterapia contra el cancer. | |
| AR104635A1 (es) | COMPOSICIONES A BASE DE LISTERIA INMUNOGÉNICA QUE COMPRENDEN FUSIONES DE ANTÍGENO Y ActA TRUNCADA Y MÉTODOS DE USO DE ESTAS | |
| MX2021006017A (es) | Polipeptidos de folistatina y sus usos. | |
| MX2018004598A (es) | Cepas vacunales recombinantes de listeria y métodos para usar las mismas en la inmunoterapia contra el cáncer. | |
| EA201691631A1 (ru) | Иммунотерапия рака с применением комбинации местной и системной иммунной стимуляции | |
| MX2019000215A (es) | Composiciones inmunogenicas a base de listeria que comprenden antigenos de proteinas del tumor de wilms y metodos para su uso. | |
| MX2017011246A (es) | Composiciones a base de listeria que comprenden un sistema de expresion de minigen peptidico y metodos de uso de estas. | |
| ZA202206809B (en) | Hiv vaccines comprising one or more population episensus antigens | |
| BR112018073221A2 (pt) | métodos de previsão da utilidade de proteínas ou seus fragmentos, métodos de seleção e/ou avaliação de modificações de aminoácidos específicas, método de fornecimento de vacinas e vacina | |
| WO2019006401A3 (en) | LISTERIA-BASED IMMUNOGENIC COMPOSITIONS COMPRISING HETERICCLIENT WILMS TUMOR PROTEIN ANTIGENS AND METHODS OF USE THEREOF | |
| MX2019003970A (es) | Péptidos de arginasa inmunogénicos. | |
| ZA202204223B (en) | Vaccination with mica/b alpha 3 domain for the treatment of cancer | |
| IN2014DN09445A (es) | ||
| WO2016011432A3 (en) | Identification of immunogenic mhc class ii peptides for immune-based therapy | |
| MX2017016438A (es) | Polipeptido quimerico, vacuna contra la babesiosis, metodos de inmunizacion, metodos de deteccion y kit. | |
| BR112017002193A2 (pt) | peptídeo derivado de urlc10 e vacina contendo o mesmo | |
| MX2016003470A (es) | Identificacion de proteinas inmunogenicas para el control de ectoparasitos. | |
| AR104231A1 (es) | Proteínas de fusión inmunogénicas para el tratamiento del cáncer | |
| MX2021001641A (es) | Identificacion de proteinas inmunogenicas para el control de ectoparasitos. |